Irinotecan Kabi

Irinotecan, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats metastatic colorectal cancer and other solid tumors in adult patients.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is used in oncology to target cancers that rely on topoisomerase I activity.

- Metastatic colorectal cancer: improves overall response rates when combined with fluoropyrimidine‑based regimens. - Advanced gastric cancer: used as part of combination chemotherapy to achieve tumor shrinkage. - Pancreatic adenocarcinoma: incorporated into multi‑agent protocols to extend progression‑free survival.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Diarrhea: often delayed, may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Severe neutropenic fever: high fever with low neutrophil count requiring urgent care. - Acute cholinergic syndrome: abdominal cramps, sweating, and bradycardia. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.

Before initiating Irinotecan therapy, clinicians should assess patient-specific risk factors and monitor laboratory parameters.

- Baseline blood counts: obtain CBC to detect pre‑existing neutropenia. - Liver function: evaluate hepatic enzymes as Irinotecan metabolism is hepatic. - Renal function: adjust monitoring for patients with impaired clearance. - Concomitant medications: review for agents that may increase toxicity, such as CYP3A4 inhibitors. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or infant risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several drug classes that can modify its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase SN‑38 exposure and toxicity. - UGT1A1 inhibitors (e.g., atazanavir): can elevate active metabolite levels, raising risk of neutropenia. - Anticholinergic agents: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as Irinotecan may affect coagulation. - Myelosuppressive chemotherapy (e.g., carboplatin): increase risk of severe bone‑marrow suppression. - Fluoropyrimidines (e.g., 5‑FU): require dose adjustments to manage overlapping toxicities.